Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of UCB-MNCs for Refractory Neonatal Diseases
NCT06427642Recruiting
- Sponsor
- Shandong Qilu Stem Cell Engineering
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of umbilical cord blood-derived mononuclear cells in hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD) and short bowel syndrome (SBS) (6 arms), sponsored by Shandong Qilu Stem Cell Engineering. Primary endpoint: Incidence of adverse reactions at 12 hours. Started Apr 2022; status: recruiting.
02
Drugs
umbilical cord blood-derived mononuclear cells
03
Conditions
hypoxic-ischemic encephalopathy (HIE)bronchopulmonary dysplasia (BPD)short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT06427642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427642.